CN111393380A - Capsaicin receptor antagonist for treating chronic inflammatory pain - Google Patents
Capsaicin receptor antagonist for treating chronic inflammatory pain Download PDFInfo
- Publication number
- CN111393380A CN111393380A CN202010335346.2A CN202010335346A CN111393380A CN 111393380 A CN111393380 A CN 111393380A CN 202010335346 A CN202010335346 A CN 202010335346A CN 111393380 A CN111393380 A CN 111393380A
- Authority
- CN
- China
- Prior art keywords
- methoxyphenyl
- chloro
- amine
- pyrazin
- benzamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
The invention discloses a capsaicin receptor antagonist 2- (4- (5- ((3-methoxyphenyl) amido) pyrazine-2-group) piperazine-1-group) benzamide for treating chronic inflammatory pain and a synthesis process thereof. The 2, 5-dichloropyrazine and 3-methoxyaniline have substitution reaction under the action of potassium tert-butoxide to obtain 5-chloro-N- (3-methoxyphenyl) pyrazine-2-amine. Subsequently, 5-chloro-N- (3-methoxyphenyl) pyrazin-2-amine and 2- (piperazin-1-yl) benzamide are subjected to Buchwald-Hartwig coupling reaction to obtain 2- (4- (5- ((3-methoxyphenyl) amino) pyrazin-2-yl) piperazin-1-yl) benzamide. The substance can be used as a medicine for treating diseases related to chronic inflammatory pain.
Description
The invention relates to a divisional application of a Chinese patent 'capsaicin receptor antagonist for treating chronic inflammatory pain and a synthesis process', wherein the application date is 7 and 9 days in 2018, and the application number is 201810744364.9.
Technical Field
The invention belongs to the field of medicine synthesis, and particularly relates to a capsaicin receptor antagonist for treating chronic inflammatory pain and a synthesis process thereof.
Background
Chronic pain can be classified, according to the pain pathology, into nociceptive or inflammatory pain (an appropriate response to a pain stimulus) and neuropathic pain (an inappropriate response induced by damage to the nervous system). The International Association for the Study of Pain (IASP) defines Pain as "unpleasant feeling and emotional experience with real or potential tissue damage or the like". Chronic pain generally refers to pain that persists for more than 1 month after the acute tissue injury subsides, or that recurs for more than 3 months. Chronic pain may be a symptom of a disease of an internal organ or may be a primary symptom of a disease. Common chronic pain includes: more than 40 of muscular fascia strain, cervical spondylosis, intervertebral disc protrusion, trigeminal neuralgia, limb joint pain, osteoporosis, cancer pain, postherpetic neuralgia, migraine, scapulohumeral periarthritis, tennis elbow, vasculitis, postamputation phantom pain and the like, and the pathogenesis and pathogenesis of the pain are complicated. The drugs currently used for analgesia include acetaminophen, non-steroidal anti-inflammatory analgesics (NSAIDs, such as salicylates), opioids (such as tramadol and morphine), and the like. Other non-analgesics, such as tricyclic antidepressants and antiepileptics, have also been used to relieve symptoms of neuropathic pain. These drugs are generally indicated for various acute pains, but many are addictive and not suitable for long-term use.
Studies have shown (J.Neurosci.2006,26: 9385-.
Transient receptor potential cation channel subfamily V member 1(the transient receptor potential channel subset V member 1, TRPV1), also known as the capsaicin receptor and the vanilloid receptor (the vanilloid receptor 1), is a protein encoded by the human TRPV1 gene. Capsaicin receptor is a selective cation channel that can be activated by a variety of exogenous and endogenous physical and chemical stimuli. The best known capsaicin receptor activators are mustard and the spicy component allyl isothiocyanate in mustard. Activation of capsaicin receptors causes painful, burning sensations, and endogenous activators include cannabis.
Nociceptors, which are morphologically the nerve endings of primary sensory neurons, are widely distributed in skin, muscle, joints and internal organs, and 80% of them are polytype nociceptors, i.e., receptors that can sense multiple stimuli, such as thermal, mechanical and chemical stimuli, and transmit these nociceptive information to the center, ultimately causing pain and discomfort sensations, and producing appropriate protective reflexes. Capsaicin receptors are widely distributed on these nociceptors, and gene knockout approaches have proven necessary to produce thermal hyperalgesia. With the continued intensive research on capsaicin receptors and the subsequent discovery of new members of its family, there is increasing evidence that capsaicin receptors are involved in the mechanism of pain development.
The Angel Messeguer, the institute of advanced chemistry, California, Spain, discovered TRPV1 antagonists with therapeutic potential (Pain 2008,136, 202-210.). However, it is disappointing that none of these drug candidates entered clinical trials due to unpredictable side effects causing fever and the like.
In view of the important role of capsaicin receptor in the pain generating mechanism, there is a need to develop a capsaicin receptor antagonist with potential application value in the treatment of chronic inflammatory pain. In order to further develop the subsequent pharmaceutical tests and medical applications of capsaicin receptor antagonists, it is also necessary to develop an application process capable of large-scale preparation.
Disclosure of Invention
In order to solve the problems, the invention provides a novel compound 2- (4- (5- ((3-methoxyphenyl) amino) pyrazin-2-yl) piperazin-1-yl) benzamide, which is taken as a capsaicin receptor antagonist with potential application value in treating chronic inflammatory pain.
Meanwhile, the invention also provides a process method for preparing the capsaicin receptor antagonist 2- (4- (5- ((3-methoxyphenyl) amido) pyrazine-2-group) piperazine-1-group) benzamide in a large scale, so that the purity of the capsaicin receptor antagonist can meet the requirement of subsequent pharmaceutical tests.
The invention provides a compound 2- (4- (5- ((3-methoxyphenyl) amido) pyrazin-2-yl) piperazine-1-yl) benzamide, which can be used as a capsaicin receptor antagonist for treating chronic inflammatory pain, and the structural formula is as follows:
the invention adopts the following process route to synthesize the capsaicin receptor antagonist 2- (4- (5- ((3-methoxyphenyl) amino) pyrazin-2-yl) piperazin-1-yl) benzamide for treating chronic inflammatory pain:
in the synthesis method, 1 is 2, 5-dichloropyrazine; 2 is 5-chloro-N- (3-methoxyphenyl) pyrazin-2-amine.
In the synthesis method, the synthesis process of 5-chloro-N- (3-methoxyphenyl) pyrazine-2-amine is (gram equivalent and volume multiple are measured relative to 2, 5-dichloropyrazine, and the gram equivalent is molar mass/(the number of elements of acid or alkali)):
mixing 2, 5-dichloropyrazine, 3-methoxyaniline (1-3 g equivalent), alkali B1(1-5 g equivalent) and solvent S1(1-20 times volume), heating to 40-70 ℃, and stirring for 2-6 hours; cooling to 15-25 ℃, adding a solvent S2(1-20 times volume) into the system, stirring for 2-5 hours, and filtering to obtain the 5-chloro-N- (3-methoxyphenyl) pyrazine-2-amine.
The base B1 is one or more selected from potassium carbonate, triethylamine, diisopropylethylamine, potassium hydroxide and potassium tert-butoxide. Further, the preferred base B1 is diisopropylethylamine, potassium hydroxide or potassium tert-butoxide, and the most preferred base B1 is potassium tert-butoxide.
The solvent S1 is selected from dimethylformamide, N-methylpyrrolidone, dioxane, tetrahydrofuran, dichloromethane or any mixed solvent thereof. Further, the preferred solvent S1 is dimethylformamide, N-methylpyrrolidone, methylene chloride or any mixed solvent thereof.
The solvent S2 is selected from one or more of water, methyl tert-butyl ether, toluene, ethyl acetate and petroleum ether. Further, preferred solvent S2 is water, methyl t-butyl ether or petroleum ether.
In the invention, the synthesis conditions of the 5-chloro-N- (3-methoxyphenyl) pyrazine-2-amine are as follows: wherein the molar ratio of the dosage of the alkali B1 to the dosage of the 2, 5-dichloropyrazine is 1-5: 1; the molar ratio of the dosage of the 3-methoxyaniline to the dosage of the 2, 5-dichloropyrazine is 1-3: 1; the volume ratio of the dosage of the solvent S1 to the dosage of the 2, 5-dichloropyrazine is 1-20: 1; the volume ratio of the dosage of the solvent S2 to the dosage of the 2, 5-dichloropyrazine is 1-20: 1.
in the synthesis method, the synthesis process of 2- (4- (5- ((3-methoxyphenyl) amino) pyrazin-2-yl) piperazin-1-yl) benzamide is (gram equivalent, volume multiple are measured relative to 5-chloro-N- (3-methoxyphenyl) pyrazin-2-amine, and gram equivalent is molar mass/(number of elements of acid or alkali)):
mixing 5-chloro-N- (3-methoxyphenyl) pyrazin-2-amine, 2- (piperazin-1-yl) benzamide (1-5 g equivalent), base B2(1-5 g equivalent), catalyst C (0.1-1 g equivalent), ligand L (0.1-1 g equivalent) and solvent S3(1-20 times volume), heating to 60-100 ℃ under nitrogen protection, stirring for 6-10 hours, filtering, adding solvent S4(1-20 times volume) to the filtrate, stirring for 2-4 hours, and filtering to obtain 2- (4- (5- ((3-methoxyphenyl) amino) pyrazin-2-yl) piperazin-1-yl) benzamide.
The solvent S3 is selected from dimethylformamide, N-methylpyrrolidone, toluene, tetrahydrofuran, water or any mixed solvent thereof. Further, preferred solvent S3 is dimethylformamide, tetrahydrofuran, toluene, water or any mixed solvent thereof.
The solvent S4 is selected from one or more of water, toluene, tetrahydrofuran, ethyl acetate, petroleum ether and n-heptane. Further, preferred solvents S4 are toluene, water or n-heptane.
The base B2 is one or more selected from potassium carbonate, sodium carbonate, cesium carbonate, potassium tert-butoxide and sodium tert-butoxide. Further, the preferred base B2 is potassium carbonate, cesium carbonate or potassium tert-butoxide.
The catalyst C is selected from one or more of tetrakis (triphenylphosphine) palladium, tris (dibenzylideneacetone) dipalladium (0), palladium acetate and palladium dichloride. Further, preferred catalysts C are tris (dibenzylideneacetone) dipalladium (0), palladium acetate or tetrakis (triphenylphosphine) palladium.
Ligand L is selected from one or more of triphenylphosphine, tris (o-methylphenyl) phosphine, 2 '-bis (diphenylphosphino) -1, 1' -binaphthyl, 1 '-bis (diphenylphosphino) ferrocene, 1, 2-bis (diphenylphosphino) ethane, and 1, 2-bis (diphenylphosphino) propane, further, preferred ligand L is 2, 2' -bis (diphenylphosphino) -1,1 '-binaphthyl, 1' -bis (diphenylphosphino) ferrocene, or 1, 2-bis (diphenylphosphino) propane.
In the invention, the synthesis conditions of the 2- (4- (5- ((3-methoxyphenyl) amino) pyrazine-2-yl) piperazine-1-yl) benzamide are that the ratio of the dosage of the solvent S3 to the dosage of the 5-chloro-N- (3-methoxyphenyl) pyrazine-2-amine in volume is 1-20: 1, the ratio of the dosage of the solvent S4 to the dosage of the 5-chloro-N- (3-methoxyphenyl) pyrazine-2-amine in volume is 1-20: 1, the ratio of the dosage of the alkali B2 to the dosage of the 5-chloro-N- (3-methoxyphenyl) pyrazine-2-amine in mole is 1-5: 1, the ratio of the dosage of the 2- (piperazine-1-yl) benzamide to the dosage of the 5-chloro-N- (3-methoxyphenyl) pyrazine-2-amine in mole is 1-5: 1, the ratio of the dosage of the catalyst C to the dosage of the 5-chloro-N- (3-methoxyphenyl) pyrazine-2-amine in mole is 0.1-1: 1, and the ratio of the dosage of the ligand C to the dosage of the 5-chloro-N- (3-methoxyphenyl) pyrazine-2-amine in mole is 0.1-1.
In the invention, 2, 5-dichloropyrazine and 3-methoxyaniline carry out substitution reaction under the action of potassium tert-butoxide to obtain 5-chloro-N- (3-methoxyphenyl) pyrazine-2-amine. Subsequently, 5-chloro-N- (3-methoxyphenyl) pyrazin-2-amine and 2- (piperazin-1-yl) benzamide are subjected to Buchwald-Hartwig coupling reaction to obtain 2- (4- (5- ((3-methoxyphenyl) amino) pyrazin-2-yl) piperazin-1-yl) benzamide. The substance can be used as a medicine for treating diseases related to chronic inflammatory pain.
The synthesis conditions and the method used in the invention have the advantages of simple operation, cheap and easily-purchased raw materials and short production period, can be used for preparing the 5-hydroxytryptamine receptor antagonist 2- (4- (5- ((3-methoxyphenyl) amino) pyrazin-2-yl) piperazin-1-yl) benzamide in a large scale, and provides enough compound 2- (4- (5- ((3-methoxyphenyl) amino) pyrazin-2-yl) piperazin-1-yl) benzamide for subsequent pharmaceutical tests.
Detailed Description
The invention will be further illustrated with reference to specific examples:
example 1
A compound 2- (4- (5- ((3-methoxyphenyl) amino) pyrazin-2-yl) piperazin-1-yl) benzamide, useful as a capsaicin receptor antagonist for the treatment of chronic inflammatory pain, having the formula:
the synthesis method of the capsaicin receptor antagonist 2- (4- (5- ((3-methoxyphenyl) amido) pyrazin-2-yl) piperazidine-1-yl) benzamide comprises the following steps:
wherein, the synthesis conditions of the 5-chloro-N- (3-methoxyphenyl) pyrazine-2-amine are as follows:
2, 5-dichloropyrazine (58.5g), 3-methoxyaniline (53.2g), potassium tert-butoxide (70.6g) and dimethylformamide (300m L) were mixed, heated to 40 ℃ and stirred for 2 hours, and methyl tert-butyl ether (600m L) was added to the system under cooling to 15 ℃ and stirred for 2 hours, followed by filtration to give 5-chloro-N- (3-methoxyphenyl) pyrazin-2-amine (72.7g, 74%).
1H NMR(CDCl3,400MHz):(ppm)＝8.22(s,1H),8.16(s,1H),7.31(t,1H),7.12-6.94(m,3H),5.29(brs,1H),4.44(s,2H),3.78(s,3H)；13C NMR(CDCl3,100MHz):(ppm)＝160.3,155.8,144.7,141.2,139.4,136.7,129.3,119.4,112.6,111.1,55.4,43.8；m/z(MS-ESI):250.77[M+1]+.
The synthesis conditions of the 2- (4- (5- ((3-methoxyphenyl) amino) pyrazin-2-yl) piperazin-1-yl) benzamide are as follows:
5-chloro-N- (3-methoxyphenyl) pyrazin-2-amine (64.8g), 2- (piperazin-1-yl) benzamide (96.1g), cesium carbonate (254.2g), tris (dibenzylideneacetone) dipalladium (0) (64.8g), 1, 2-bis (diphenylphosphino) propane (38.9g) and tetrahydrofuran (350m L) were mixed, heated to 60-100 ℃ under nitrogen protection, stirred for 6 hours, filtered, water (500m L) was added to the filtrate, stirred for 2 hours, and filtered to give 2- (4- (5- ((3-methoxyphenyl) amino) pyrazin-2-yl) piperazin-1-yl) benzamide (71.6g, 68%).
1H NMR(CDCl3,400MHz):(ppm)＝3.28(t,4H),3.57(t,4H),3.78(s,3H),6.49(d,1H),6.67(d,1H),6.80(s,1H),6.91(d,1H),7.21(dd,1H),7.31(d,1H),7.42–7.36(m,1H),7.59(d,1H),7.65(s,2H),7.96(brs,2H),8.87(brs,1H)；13C NMR(CDCl3,100MHz):(ppm)＝48.5,49.5,55.8,99.4,110.1,110.8,115.9,117.2,118.3,128.4,130.5,133.3,135.2,143.4,145.6,145.6,149.1,161.4,172.8；m/z(MS-ESI):404.75[M+1]+.
Example 2
A compound 2- (4- (5- ((3-methoxyphenyl) amino) pyrazin-2-yl) piperazin-1-yl) benzamide, useful as a capsaicin receptor antagonist for the treatment of chronic inflammatory pain, having the formula:
the synthesis method of the capsaicin receptor antagonist 2- (4- (5- ((3-methoxyphenyl) amido) pyrazin-2-yl) piperazidine-1-yl) benzamide comprises the following steps:
wherein, the synthesis conditions of the 5-chloro-N- (3-methoxyphenyl) pyrazine-2-amine are as follows:
mixing 2, 5-dichloropyrazine (58.5g), 3-methoxyaniline (106.4g), diisopropylethylamine (141.2g) and N-methylpyrrolidone (600m L), heating to 50 ℃, stirring for 3 hours, cooling to 20 ℃, adding petroleum ether (900m L), stirring for 3 hours, and filtering to obtain 5-chloro-N- (3-methoxyphenyl) pyrazin-2-amine (80g, 70%).
1H NMR(CDCl3,400MHz):(ppm)＝8.22(s,1H),8.16(s,1H),7.31(t,1H),7.12-6.94(m,3H),5.29(brs,1H),4.44(s,2H),3.78(s,3H)；13C NMR(CDCl3,100MHz):(ppm)＝160.3,155.8,144.7,141.2,139.4,136.7,129.3,119.4,112.6,111.1,55.4,43.8；m/z(MS-ESI):250.77[M+1]+.
The synthesis conditions of the 2- (4- (5- ((3-methoxyphenyl) amino) pyrazin-2-yl) piperazin-1-yl) benzamide are as follows:
5-chloro-N- (3-methoxyphenyl) pyrazin-2-amine (64.8g), 2- (piperazin-1-yl) benzamide (192.2g), potassium carbonate (508.4g), a mixture of tris (dibenzylideneacetone) dipalladium (0) and palladium dichloride (7.0g), 1' -bis (diphenylphosphino) ferrocene (3.9g) and a solvent (700m L) mixed with dimethylformamide, tetrahydrofuran, toluene, water were mixed, heated to 70 ℃ under nitrogen protection, stirred for 7 hours, filtered, toluene (1000m L) was added to the filtrate, stirred for 3 hours, filtered to give 2- (4- (5- ((3-methoxyphenyl) amino) pyrazin-2-yl) piperazin-1-yl) benzamide (89g, 64%).
1H NMR(CDCl3,400MHz):(ppm)＝3.28(t,4H),3.57(t,4H),3.78(s,3H),6.49(d,1H),6.67(d,1H),6.80(s,1H),6.91(d,1H),7.21(dd,1H),7.31(d,1H),7.42–7.36(m,1H),7.59(d,1H),7.65(s,2H),7.96(brs,2H),8.87(brs,1H)；13C NMR(CDCl3,100MHz):(ppm)＝48.5,49.5,55.8,99.4,110.1,110.8,115.9,117.2,118.3,128.4,130.5,133.3,135.2,143.4,145.6,145.6,149.1,161.4,172.8；m/z(MS-ESI):404.75[M+1]+.
Example 3
A compound 2- (4- (5- ((3-methoxyphenyl) amino) pyrazin-2-yl) piperazin-1-yl) benzamide, useful as a capsaicin receptor antagonist for the treatment of chronic inflammatory pain, having the formula:
the synthesis method of the capsaicin receptor antagonist 2- (4- (5- ((3-methoxyphenyl) amido) pyrazin-2-yl) piperazidine-1-yl) benzamide comprises the following steps:
wherein, the synthesis conditions of the 5-chloro-N- (3-methoxyphenyl) pyrazine-2-amine are as follows:
mixing 2, 5-dichloropyrazine (58.5g), 3-methoxyaniline (159.6g), potassium hydroxide (211.8g) and dichloromethane (900m L), heating to 40-70 ℃, stirring for 4 hours, cooling to 22 ℃, adding water (1200m L), stirring for 4 hours, and filtering to obtain 5-chloro-N- (3-methoxyphenyl) pyrazine-2-amine (134g, 84%).
1H NMR(CDCl3,400MHz):(ppm)＝8.22(s,1H),8.16(s,1H),7.31(t,1H),7.12-6.94(m,3H),5.29(brs,1H),4.44(s,2H),3.78(s,3H)；13C NMR(CDCl3,100MHz):(ppm)＝160.3,155.8,144.7,141.2,139.4,136.7,129.3,119.4,112.6,111.1,55.4,43.8；m/z(MS-ESI):250.77[M+1]+.
The synthesis conditions of the 2- (4- (5- ((3-methoxyphenyl) amino) pyrazin-2-yl) piperazin-1-yl) benzamide are as follows:
5-chloro-N- (3-methoxyphenyl) pyrazin-2-amine (64.8g), 2- (piperazin-1-yl) benzamide (288.3g), potassium tert-butoxide (762.6g), palladium dichloride (14.0g), 2 '-bis (diphenylphosphino) -1, 1' -binaphthyl (7.8g) and water (1500m L) were mixed, heated to 70 ℃ under nitrogen protection and stirred for 7 hours, and filtered, and N-heptane (2500m L) was added to the filtrate, stirred for 3.5 hours, and filtered to give 2- (4- (5- ((3-methoxyphenyl) amino) pyrazin-2-yl) piperazin-1-yl) benzamide (133g, 88%).
1H NMR(CDCl3,400MHz):(ppm)＝3.28(t,4H),3.57(t,4H),3.78(s,3H),6.49(d,1H),6.67(d,1H),6.80(s,1H),6.91(d,1H),7.21(dd,1H),7.31(d,1H),7.42–7.36(m,1H),7.59(d,1H),7.65(s,2H),7.96(brs,2H),8.87(brs,1H)；13C NMR(CDCl3,100MHz):(ppm)＝48.5,49.5,55.8,99.4,110.1,110.8,115.9,117.2,118.3,128.4,130.5,133.3,135.2,143.4,145.6,145.6,149.1,161.4,172.8；m/z(MS-ESI):404.75[M+1]+.
Example 4
A compound 2- (4- (5- ((3-methoxyphenyl) amino) pyrazin-2-yl) piperazin-1-yl) benzamide, useful as a capsaicin receptor antagonist for the treatment of chronic inflammatory pain, having the formula:
the synthesis method of the capsaicin receptor antagonist 2- (4- (5- ((3-methoxyphenyl) amido) pyrazin-2-yl) piperazidine-1-yl) benzamide comprises the following steps:
wherein, the synthesis conditions of the 5-chloro-N- (3-methoxyphenyl) pyrazine-2-amine are as follows:
2, 5-dichloropyrazine (58.5g), 3-methoxyaniline (159.6g), triethylamine (282.4g) and a solvent (3000m L) mixed by dimethylformamide, N-methylpyrrolidone and dioxane were mixed, heated to 70 ℃, stirred for 6 hours, cooled to 25 ℃, added with ethyl acetate (1600m L), stirred for 5 hours, and filtered to obtain 5-chloro-N- (3-methoxyphenyl) pyrazin-2-amine (152.7g, 89%).
1H NMR(CDCl3,400MHz):(ppm)＝8.22(s,1H),8.16(s,1H),7.31(t,1H),7.12-6.94(m,3H),5.29(brs,1H),4.44(s,2H),3.78(s,3H)；13C NMR(CDCl3,100MHz):(ppm)＝160.3,155.8,144.7,141.2,139.4,136.7,129.3,119.4,112.6,111.1,55.4,43.8；m/z(MS-ESI):250.77[M+1]+.
The synthesis conditions of the 2- (4- (5- ((3-methoxyphenyl) amino) pyrazin-2-yl) piperazin-1-yl) benzamide are as follows:
5-chloro-N- (3-methoxyphenyl) pyrazin-2-amine (64.8g), 2- (piperazin-1-yl) benzamide (294.4g), sodium carbonate (1016.8g), tetrakis (triphenylphosphine) palladium (28.0g), 1, 2-bis (diphenylphosphino) ethane (18.7g) and toluene (3800m L) were mixed, heated to 80 ℃ under nitrogen protection, stirred for 8 hours, filtered, ethyl acetate (5000m L) was added to the filtrate, stirred for 4 hours, and filtered to give 2- (4- (5- ((3-methoxyphenyl) amino) pyrazin-2-yl) piperazin-1-yl) benzamide (145g, 77%).
1H NMR(CDCl3,400MHz):(ppm)＝3.28(t,4H),3.57(t,4H),3.78(s,3H),6.49(d,1H),6.67(d,1H),6.80(s,1H),6.91(d,1H),7.21(dd,1H),7.31(d,1H),7.42–7.36(m,1H),7.59(d,1H),7.65(s,2H),7.96(brs,2H),8.87(brs,1H)；13C NMR(CDCl3,100MHz):(ppm)＝48.5,49.5,55.8,99.4,110.1,110.8,115.9,117.2,118.3,128.4,130.5,133.3,135.2,143.4,145.6,145.6,149.1,161.4,172.8；m/z(MS-ESI):404.75[M+1]+.
Example 5
A compound 2- (4- (5- ((3-methoxyphenyl) amino) pyrazin-2-yl) piperazin-1-yl) benzamide, useful as a capsaicin receptor antagonist for the treatment of chronic inflammatory pain, having the formula:
the synthesis method of the capsaicin receptor antagonist 2- (4- (5- ((3-methoxyphenyl) amido) pyrazin-2-yl) piperazidine-1-yl) benzamide comprises the following steps:
wherein, the synthesis conditions of the 5-chloro-N- (3-methoxyphenyl) pyrazine-2-amine are as follows:
mixing 2, 5-dichloropyrazine (58.5g), 3-methoxyaniline (159.6g), potassium carbonate (353g) and a solvent (6000m L) mixed by dimethylformamide, N-methylpyrrolidone and dichloromethane, heating to 70 ℃, stirring for 6 hours, cooling to 25 ℃, adding a solvent (6000m L) mixed by water, methyl tert-butyl ether and toluene into the system, stirring for 5 hours, and filtering to obtain 5-chloro-N- (3-methoxyphenyl) pyrazine-2-amine (272.7g, 84%).
1H NMR(CDCl3,400MHz):(ppm)＝8.22(s,1H),8.16(s,1H),7.31(t,1H),7.12-6.94(m,3H),5.29(brs,1H),4.44(s,2H),3.78(s,3H)；13C NMR(CDCl3,100MHz):(ppm)＝160.3,155.8,144.7,141.2,139.4,136.7,129.3,119.4,112.6,111.1,55.4,43.8；m/z(MS-ESI):250.77[M+1]+.
The synthesis conditions of the 2- (4- (5- ((3-methoxyphenyl) amino) pyrazin-2-yl) piperazin-1-yl) benzamide are as follows:
5-chloro-N- (3-methoxyphenyl) pyrazin-2-amine (64.8g), 2- (piperazin-1-yl) benzamide (480.5g), sodium tert-butoxide (1271.0g), palladium acetate (62.1g), tris (o-methylphenyl) phosphine (64.8g) and dimethylformamide (7000m L) were mixed, heated to 100 ℃ under nitrogen protection and stirred for 10 hours, filtered, petroleum ether (10000m L) was added to the filtrate and stirred for 4 hours to give 2- (4- (5- ((3-methoxyphenyl) amino) pyrazin-2-yl) piperazin-1-yl) benzamide (171.6g, 78%).
1H NMR(CDCl3,400MHz):(ppm)＝3.28(t,4H),3.57(t,4H),3.78(s,3H),6.49(d,1H),6.67(d,1H),6.80(s,1H),6.91(d,1H),7.21(dd,1H),7.31(d,1H),7.42–7.36(m,1H),7.59(d,1H),7.65(s,2H),7.96(brs,2H),8.87(brs,1H)；13C NMR(CDCl3,100 MHz):(ppm)＝48.5,49.5,55.8,99.4,110.1,110.8,115.9,117.2,118.3,128.4,130.5,133.3,135.2,143.4,145.6,145.6,149.1,161.4,172.8；m/z(MS-ESI):404.75[M+1]+.
Claims (10)
1. A capsaicin receptor antagonist for use in the treatment of chronic inflammatory pain, wherein the capsaicin receptor antagonist is the compound 2- (4- (5- ((3-methoxyphenyl) amino) pyrazin-2-yl) piperazin-1-yl) benzamide, having the formula:
the synthetic process route is as follows:
2. a capsaicin receptor antagonist for use in the treatment of chronic inflammatory pain according to claim 1, wherein 2- (4- (5- ((3-methoxyphenyl) amino) pyrazin-2-yl) piperazin-1-yl) benzamide is prepared by the steps of:
(1) carrying out substitution reaction on 2, 5-dichloropyrazine and 3-methoxyaniline under the action of potassium tert-butoxide to obtain 5-chloro-N- (3-methoxyphenyl) pyrazine-2-amine;
(2) the 5-chloro-N- (3-methoxyphenyl) pyrazine-2-amine and 2- (piperazine-1-yl) benzamide are subjected to Buchwald-Hartwig coupling reaction to obtain the 2- (4- (5- ((3-methoxyphenyl) amino) pyrazine-2-yl) piperazine-1-yl) benzamide.
3. A capsaicin receptor antagonist according to claim 2, wherein 5-chloro-N- (3-methoxyphenyl) pyrazin-2-amine is synthesized by:
(1) mixing 2, 5-dichloropyrazine, 3-methoxyaniline, alkali B1 and solvent S1, heating to 40-70 ℃, and stirring for 2-6 hours;
(2) cooling to 15-25 ℃, adding a solvent S2 into the system, stirring for 2-5 hours, and filtering to obtain the 5-chloro-N- (3-methoxyphenyl) pyrazine-2-amine.
4. A capsaicin receptor antagonist for use in the treatment of chronic inflammatory pain according to claim 2, wherein base B1 is chosen from one or more of potassium carbonate, triethylamine, diisopropylethylamine, potassium hydroxide and potassium tert-butoxide, in a molar ratio to 2, 5-dichloropyrazine of (1-5): 1; the molar ratio of the dosage of the 3-methoxyaniline to the dosage of the 2, 5-dichloropyrazine is (1-3): 1.
5. a capsaicin receptor antagonist for use in the treatment of chronic inflammatory pain according to claim 2, wherein solvent S1 is selected from the group consisting of dimethylformamide, N-methylpyrrolidone, dioxane, tetrahydrofuran, dichloromethane, and any mixture thereof, in a ratio to the volume of 2, 5-dichloropyrazine of (1-20): 1; the solvent S2 is selected from one or more of water, methyl tert-butyl ether, toluene, ethyl acetate and petroleum ether, and the volume ratio of the dosage to the dosage of the 2, 5-dichloropyrazine is (1-20): 1.
6. a capsaicin receptor antagonist according to claim 2, wherein 2- (4- (5- ((3-methoxyphenyl) amino) pyrazin-2-yl) piperazin-1-yl) benzamide is synthesized by:
(1) mixing 5-chloro-N- (3-methoxyphenyl) pyrazine-2-amine, 2- (piperazin-1-yl) benzamide, alkali B2, catalyst C, ligand L and solvent S3, heating to 60-100 ℃ under the protection of nitrogen, and stirring for 6-10 hours;
(2) filtering, adding a solvent S4 into the filtrate, stirring for 2-4 hours, and filtering to obtain the 2- (4- (5- ((3-methoxyphenyl) amino) pyrazin-2-yl) piperazin-1-yl) benzamide.
7. The capsaicin receptor antagonist for treating chronic inflammatory pain according to claim 6, wherein the solvent S3 is selected from dimethylformamide, N-methylpyrrolidone, toluene, tetrahydrofuran, water, or any mixture thereof, and the volume ratio of the solvent S3 to the 5-chloro-N- (3-methoxyphenyl) pyrazin-2-amine is (1-20): 1; the solvent S4 is selected from one or more of water, toluene, tetrahydrofuran, ethyl acetate, petroleum ether and N-heptane, and the volume ratio of the dosage to the dosage of 5-chloro-N- (3-methoxyphenyl) pyrazine-2-amine is (1-20): 1.
8. a capsaicin receptor antagonist for use in the treatment of chronic inflammatory pain according to claim 6, wherein base B2 is selected from one or more of potassium carbonate, sodium carbonate, cesium carbonate, potassium tert-butoxide and sodium tert-butoxide, in a molar ratio to 5-chloro-N- (3-methoxyphenyl) pyrazin-2-amine (1-5): 1; the molar ratio of the dosage of the 2- (piperazine-1-yl) benzamide to the molar dosage of the 5-chloro-N- (3-methoxyphenyl) pyrazine-2-amine is (1-5): 1.
9. a capsaicin receptor antagonist according to claim 6, wherein catalyst C is selected from one or more of tetrakis (triphenylphosphine) palladium, tris (dibenzylideneacetone) dipalladium (0), palladium acetate and palladium dichloride, in a molar ratio to 5-chloro-N- (3-methoxyphenyl) pyrazin-2-amine (0.1-1): 1.
10. the capsaicin receptor antagonist for treating chronic inflammatory pain according to claim 6, wherein ligand L is one or more selected from the group consisting of triphenylphosphine, tris (o-methylphenyl) phosphine, 2 ' -bis (diphenylphosphino) -1,1 ' -binaphthyl, 1 ' -bis (diphenylphosphino) ferrocene, 1, 2-bis (diphenylphosphino) ethane, and 1, 2-bis (diphenylphosphino) propane, in a molar ratio to 5-chloro-N- (3-methoxyphenyl) pyrazin-2-amine of (0.1-1): 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010335346.2A CN111393380A (en) | 2018-07-09 | 2018-07-09 | Capsaicin receptor antagonist for treating chronic inflammatory pain |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010335346.2A CN111393380A (en) | 2018-07-09 | 2018-07-09 | Capsaicin receptor antagonist for treating chronic inflammatory pain |
| CN201810744364.9A CN108863949B (en) | 2018-07-09 | 2018-07-09 | Capsaicin receptor antagonist for treating chronic inflammatory pain and synthetic method |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810744364.9A Division CN108863949B (en) | 2018-07-09 | 2018-07-09 | Capsaicin receptor antagonist for treating chronic inflammatory pain and synthetic method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111393380A true CN111393380A (en) | 2020-07-10 |
Family
ID=64300065
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010335346.2A Withdrawn CN111393380A (en) | 2018-07-09 | 2018-07-09 | Capsaicin receptor antagonist for treating chronic inflammatory pain |
| CN201810744364.9A Active CN108863949B (en) | 2018-07-09 | 2018-07-09 | Capsaicin receptor antagonist for treating chronic inflammatory pain and synthetic method |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810744364.9A Active CN108863949B (en) | 2018-07-09 | 2018-07-09 | Capsaicin receptor antagonist for treating chronic inflammatory pain and synthetic method |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN111393380A (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060058308A1 (en) * | 2004-09-13 | 2006-03-16 | Norman Mark H | Vanilloid receptor ligands and their use in treatments |
| CN1820001A (en) * | 2003-07-10 | 2006-08-16 | 神经能质公司 | Substituted heterocyclic diarylamine analogues |
| CN1823057A (en) * | 2003-07-16 | 2006-08-23 | 神经能质公司 | Biaryl piperazinyl-pyridine analogues |
| CN1826328A (en) * | 2003-07-22 | 2006-08-30 | 神经能质公司 | Substituted pyridin-2-ylamine analogues |
| CN1953976A (en) * | 2004-02-11 | 2007-04-25 | 安进公司 | Pyrimidine derivatives for use as vanilloid receptor ligands and their use in the treatment of pain |
| CN101035780A (en) * | 2003-11-10 | 2007-09-12 | 默沙东有限公司 | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain |
| WO2008099210A2 (en) * | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
| US20090137594A1 (en) * | 2005-05-20 | 2009-05-28 | Gruenenthal Gmgh | Pentafluorosulphanyl-Substituted Compound And Its Use For Producing Medicaments |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0303623A2 (en) * | 2001-03-26 | 2004-03-01 | Novartis Ag. | Fused pyridine derivatives, process for their preparation, pharmaceutical compositions containing them for treating pain as vanilloid receptor antagonist |
| AU2004285052A1 (en) * | 2003-10-31 | 2005-05-12 | Neurogen Corporation | 4-amino (AZA) quinoline derivatives as capsaicin receptor agonists |
| US8349852B2 (en) * | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| CN102973545A (en) * | 2012-12-11 | 2013-03-20 | 中国药科大学 | Abirritation application of dicaffeoylquinic acid type capsaicin receptor antagonist |
-
2018
- 2018-07-09 CN CN202010335346.2A patent/CN111393380A/en not_active Withdrawn
- 2018-07-09 CN CN201810744364.9A patent/CN108863949B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1820001A (en) * | 2003-07-10 | 2006-08-16 | 神经能质公司 | Substituted heterocyclic diarylamine analogues |
| CN1823057A (en) * | 2003-07-16 | 2006-08-23 | 神经能质公司 | Biaryl piperazinyl-pyridine analogues |
| CN1826328A (en) * | 2003-07-22 | 2006-08-30 | 神经能质公司 | Substituted pyridin-2-ylamine analogues |
| CN101035780A (en) * | 2003-11-10 | 2007-09-12 | 默沙东有限公司 | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain |
| CN1953976A (en) * | 2004-02-11 | 2007-04-25 | 安进公司 | Pyrimidine derivatives for use as vanilloid receptor ligands and their use in the treatment of pain |
| US20060058308A1 (en) * | 2004-09-13 | 2006-03-16 | Norman Mark H | Vanilloid receptor ligands and their use in treatments |
| US20090137594A1 (en) * | 2005-05-20 | 2009-05-28 | Gruenenthal Gmgh | Pentafluorosulphanyl-Substituted Compound And Its Use For Producing Medicaments |
| WO2008099210A2 (en) * | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
Non-Patent Citations (3)
| Title |
|---|
| 戴冬艳等: "治疗疼痛新途径:瞬时受体电位香草酸亚型1拮抗剂的研究进展", 《中国药科大学学报》 * |
| 李仁利: "《药物构效关系》", 31 January 2004, 中国医药科技出版社 * |
| 马英: "《药物化学 第2版》", 31 August 2012, 河南科学技术出版社 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108863949B (en) | 2021-01-15 |
| CN108863949A (en) | 2018-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100468520B1 (en) | Novel amides compounds and the pharmaceutical compositions containing the same | |
| KR101204751B1 (en) | Carboxamido opioid compounds | |
| US20100022523A1 (en) | 3-aminobenzamide compounds and vanilloid receptor subtype 1 (vr1) inhibitors | |
| KR20140006768A (en) | Demethylase inhibitors and their medical use | |
| JPS6039347B2 (en) | 1,1,2-Triphenylbutene-1 derivatives and therapeutically compatible salts thereof, processes for their preparation and antitumor agents containing this compound | |
| CA2834548A1 (en) | Inhibitors of histone deacetylase | |
| CZ2001384A3 (en) | Amide derivatives that are useful as inhibitors of cytokine, process of their preparation and pharmaceutical preparation in which they are comprised | |
| WO2001025190A1 (en) | Novel diarylamide derivatives and use thereof as medicines | |
| JPS6277357A (en) | Phenoxyacetic acid derivative, manufacture and medicinal composition for obesity | |
| JPS6393755A (en) | Amide derivative, manufacture and medicinal composition for treating obesity and related symptoms | |
| TW200918069A (en) | Quinazolinone compounds and methods of use thereof | |
| UA77000C2 (en) | Crystalline form of hydroxynorephedrine derivative | |
| JPH06506676A (en) | Ethanolamine derivative with anti-urinary effect | |
| JPH04264067A (en) | 1-(2-arylethyl)-pyrrolidine | |
| TW200304815A (en) | NK1 antagonists | |
| JPH1072449A (en) | Benzimidazole derivative | |
| JP2706755B2 (en) | Novel benzylaminoethoxybenzene derivative | |
| JPH07507814A (en) | Substituted (arylalkoxybenzyl)aminopropanamide derivative and method for producing the same | |
| CA2340341A1 (en) | Calcilytic compounds | |
| NO180117B (en) | Analogous Process for the Preparation of Therapeutically Active Betaminoethyl-Substituted Phenyl Compounds and New Starting Compounds / Intermediates for Use Therein | |
| JPWO2005079845A1 (en) | Migraine prophylaxis | |
| CN108863949B (en) | Capsaicin receptor antagonist for treating chronic inflammatory pain and synthetic method | |
| Sadeghian-Rizi et al. | Synthesis and characterization of some novel diaryl urea derivatives bearing quinoxalindione moiety | |
| WO2006098554A1 (en) | Novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and a pharmaceutical composition containing the same | |
| TW201632508A (en) | 6-amino-5,6,7,8-tetrahydronaphthalen-2-yl or 3-aminochroman-7-yl derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200710 |
|
| WW01 | Invention patent application withdrawn after publication |